SOTIO Strengthens Leadership Team with Appointments of Amy Jensen-Smith as Chief Scientific Officer and Ulrich Moebius as Chief Development Officer
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the appointments of two accomplished scientific executives to its leadership team to support the continued progress of SOTIO’s pipeline of novel antibody-drug conjugates and immunotherapies for difficult-to-treat solid tumors. Amy Jensen-Smith, Ph.D., has been named SOTIO’s chief scientific officer, in which capacity she will oversee platform expansion and discovery research; Ulrich Moebius, Ph.D., as chief development officer, will direct the company’s translational research and drug development strategy.
SOTIO Reports Promising Preclinical Data on Antibody-Drug Conjugates SOT109 and SOT106, Underscoring Best-in-Class Potential for Solid Tumor Treatments
• SOT109 (targeting cadherin-17) exhibits potent efficacy and a favorable safety profile in preclinical models of colorectal cancer; currently in IND-enabling stage with IND filing anticipated in 2026;
• SOT106 (targeting LRRC15) exhibits robust preclinical efficacy in mesenchymal tumors, including broad subset of sarcomas.
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, this week presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL.
SOTIO to Present Preclinical Data on Lead Antibody-Drug Conjugates, SOT106 and SOT109, at 2025 AACR Annual Meeting
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new data from two of its antibody-drug conjugate (ADC) programs for the treatment of solid tumors, showcasing advancements in its innovative pipeline. The presentations will take place at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL from April 25-30, 2025.
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
